Journal
TRANSFUSION MEDICINE AND HEMOTHERAPY
Volume 40, Issue 6, Pages 388-402Publisher
KARGER
DOI: 10.1159/000357163
Keywords
Adoptive cell transfer; Chimeric antigen receptor; CAR; T-cell receptor; TCR; Clinical trial
Categories
Ask authors/readers for more resources
The broaden application of adoptive T-cell transfer has been constrained by the technical abilities to isolate and expand antigen-specific T cells potent to selectively kill tumor cells. With the recent progress in the design and manufacturing of cellular products, T cells used in the treatment of malignant diseases may be regarded as anticancer biopharmaceuticals. Genetical manipulation of T cells has given T cells desired specificity but also enable to tailor their activation and proliferation potential. Here, we summarize the recent developments in genetic engineering of T-cell-based biopharmaceuticals, covering criteria for their clinical application in regard to safety and efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available